MRIGlobal continues support for shelf life evaluations of investigational dosage forms
MRIGlobal today announced the award of a five-year contract by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) for Shelf Life Evaluation of Investigational Dosage Forms.
Valued at $2,999,743, the contract was awarded in support of NCI’s Division of Cancer Treatment and Diagnosis.
MRIGlobal has supported this program since 2002, which involves shelf-life stability analytical testing for cancer chemotherapeutic compounds that are under clinical development at the NCI. Information regarding the proper storage and handling of various drug products and determination of appropriate expiration dates for the products supports NCI’s Investigational New Drug Applications filed with the Food and Drug Administration.
“We are all working toward a world without cancer,” said Thomas M. Sack, Ph.D., MRIGlobal President and Chief Executive Officer. “Our scientists take pride in working with NCI to combat this devastating disease.”
This project is funded by the National Cancer Institute at the National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800003C.